Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Products

Set Alert for Products

Generics Explore this Topic

Set Alert for Generics

ANDA Approval Decline Continues, But Why?

US FDA says COVID disruptions may be having an impact; complete response letters have also dropped significantly.

Generic Drugs Review Pathway

Teva Likes Biosimilar Licensing Deals As It Cuts Full-Year Sales Guidance

Teva is keeping a keen eye out for opportunities like its US biosimilars agreement with Alvotech and more recent deal with Bioeq for biosimilar Lucentis as it attempts to maintain revenues in the coming years, following a cut to full-year sales guidance for 2021.

Sales & Earnings Strategy

GGB Awards Offer One More Week To Enter

Off-patent industry players from around the globe now have an extra week to submit their achievements to the Global Generics & Biosimilars Awards 2021 being held on 10 November, after the entry deadline was extended by a week to 6 August. Pharmacloud has also joined the event, sponsoring the Leader of the Year category.

Generic Drugs Biosimilars
See All

Biosimilars Explore this Topic

Set Alert for Biosimilars

Teva Likes Biosimilar Licensing Deals As It Cuts Full-Year Sales Guidance

Teva is keeping a keen eye out for opportunities like its US biosimilars agreement with Alvotech and more recent deal with Bioeq for biosimilar Lucentis as it attempts to maintain revenues in the coming years, following a cut to full-year sales guidance for 2021.

Sales & Earnings Strategy

GGB Awards Offer One More Week To Enter

Off-patent industry players from around the globe now have an extra week to submit their achievements to the Global Generics & Biosimilars Awards 2021 being held on 10 November, after the entry deadline was extended by a week to 6 August. Pharmacloud has also joined the event, sponsoring the Leader of the Year category.

Generic Drugs Biosimilars

Pfizer Takes ‘Opportunistic’ Approach To Future Biosimilars

Pfizer reported double-digit growth in its biosimilars and sterile injectables segments, as the company indicated that it would take a more “opportunistic” approach to its biosimilars business in future. The company has also revised its overall 2021 financial guidance as it expects better numbers on the back of its COVID-19 vaccine business.

Biosimilars Coronavirus COVID-19
See All

Value-Added Medicines Explore this Topic

Set Alert for Value-Added Medicines

GGB Awards Offer One More Week To Enter

Off-patent industry players from around the globe now have an extra week to submit their achievements to the Global Generics & Biosimilars Awards 2021 being held on 10 November, after the entry deadline was extended by a week to 6 August. Pharmacloud has also joined the event, sponsoring the Leader of the Year category.

Generic Drugs Biosimilars

Advanz Claims A First With German Lanreotide Launch

Advanz has claimed a first with a European launch of a rival to Ipsen’s Somatuline, introducing its generic lanreotide in Germany under the name Mytolac.

Launches Generic Drugs

Sorrento And Mabpharm Get ‘Biobetter’ Infliximab Approval In China

Sorrento and Mabpharm have revealed plans to take their infliximab “biobetter” global, after China’s NMPA approved the product, which has an improved safety profile compared to Remicade.

Biosimilars Value-Added Medicines
See All
UsernamePublicRestriction

Register

;